References
- Swanborg R. H. Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Din. Immunol. Immunopathol. 1995; 77: 4–13
- Karussis D. M., Lehmann D., Slavin S., Vourka-Karussis U., Mizrachi-Koll R., Ovadia H., et al. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator Linomide. Ann. Neurology 1993; 34: 654–60
- Karussis D. M., Lehmann D., Slavin S., Vourka-Karussis U., Mizrachi-Koll R., Ovadia H., et al. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator Linomide (quinoline-3-carboxamide). Proc. Natl. Acad. Sci. USA 1993; 90: 6400–04
- Tarkowski A., Gunnarsson K., Stålhandske T. Effects of LS-2616 administration upon the autoimmune disease of (NZBxNZW) F1 hybrid mice. Immunology 1986; 59: 589–94
- Björk J., Kleinau S. Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice. Agents and Actions 1989; 27: 319–21
- Gross D. J., Sidi H., Weiss L., Kalland T., Rosenmann E., Slavin S. Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug. Diabetologica 1994; 37: 1195–1201
- Karussis D. M., Lehmann D., Brenner T., Wirguin I., Mizrachi-Koll R., Sicsic C., et al. Immunomodulation of experimental autoimmune myasthenia gravis with Linomide. J. Neuroimmunol. 1994; 55: 187–93
- Christensen U. B., Mauricio D., Reimers J. I., Andersen H. U., Kalland T., Nerup J., Mandrup-Poulsen T. Linomide increases plasma corticosterone in normal rats, but does not prevent the inhibitory action of IL-1 on β-cells in vivo or ex vivo. Autoimmunity 1996; 23: 257–68
- MacPhee I. A. M., Antoni F. A., Mason D. W. Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids. J. Exp. Med. 1989; 169: 431–45
- Mason D., MacPhee I., Antoni F. The role of the neuroendocrine system in determining genetic susceptibility to experimental allergic encephalomyelitis in the rat. Immunology 1990; 70: 1–5
- Griffin A. C., Lo W. D., Wolny A. C., Whitacre C. C. Suppression of experimental autoimmune encephalomyelitis by restrain stress: sex differences. J. Neuroimmunol. 1993; 44: 103–16
- Reder A. T., Thapar M., Jensen M. A. A reduction in serum glucocorticoids provokes experimental allergic encephalomyelitis: Implications for treatment of inflammatory brain disease. Neurolog. 1994; 44: 2289–94
- Purba J. S., Raadsheer F. C., Hofman M. A., Ravid R., Polman C. H., Kamphorst W., et al. Increased number of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of patients with multiple sclerosis. Neuroendocrinol. 1995; 62: 62–70
- Harbuz M. S., Leonard J. P., Lightman S. L., Cuzner M. L. Changes in hypothalamic corticotrophin-releasing factor and anterior pituitary pro-opiomelanocortin mRNA during the course of experimental allergic encephalomyelitis. J. Neuroimmunol. 1993; 45: 127–32
- Besedovsky H., del Rey A., Sorkin E., Dinarello C. A. Immunoregulatory feedback between Interleukin-1 and Glucocorticoid hormones. Science 1986; 233: 652–4
- Vukanovic J., Hartley-Asp B., Isaacs J. T. Inhibition of tumor angiogenesis and the therapeutic ability of Linomide against rat prostatic cancers. The Prostate 1995; 26: 235–46
- Kroemer G. The pharmacology of T-cell apoptosis. Advances in Immunology, F. J. Dixon. Academic Press, San Diego 1995; 211–96, Vol. 58
- Kalland T., Alm G., Stålhandske T. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J. Immunol. 1985; 134: 3956–61
- Slavin S., Sidi H., Weiss L., Rosenman E., Kalland T., Gross D. Linomide, a new treatment for autoimmune diseases: The potential in Type 1 diabetes. Diabetes/Metabolism Reviews 1993; 9: 311–25
- Gonzalo J. A., González-Garcia A., Kalland T., Hedlund G., Martinez-A C., Kroemer G. Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur. J. Immunol. 1993; 23: 2372–74